Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
matsupexole
- Development stage
- Phase 2
- Lead developer
- Kissei Pharmaceutical
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
**Matsupexole** is a **small molecule** non-ergot **dopamine D2 receptor agonist** developed primarily for **Parkinson's disease**. It belongs to the class of octahydrothienoquinoline derivatives (molecular formula C22H34N6O2S) and acts by stimulating dopamine D2 receptors to alleviate motor symptoms. Originating from **Kissei Pharmaceutical**, it has been licensed to **AffaMed Therapeutics** for development in regions like China, with phase II trials completed in Japan (NCT04867551) and ongoing late phase II trials as of 2024-2025.
- Other names
- matsupexolum
02
Targets
DRD2 (Dopamine D2 Receptor)DRD3 (Dopamine receptor D3)HTR2B (5-Hydroxytryptamine Receptor 2B)
Beyond the preview
Go deeper on matsupexole.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on matsupexole.